Welcome to our dedicated page for Vir Biotechnology SEC filings (Ticker: VIR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vir Biotechnology, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage biopharmaceutical company with common stock traded under VIR. Its SEC disclosures cover operating and financial results, cash and investment updates, clinical and regulatory communications, material agreements, and capital-structure actions related to common stock issuances and collaborations.
The company’s proxy and current reports also describe board and executive governance, compensation matters, shareholder voting items, leadership changes, and registered security information. For Vir’s business model, the filings connect pipeline spending, development-stage risk factors, collaboration economics, intellectual property matters, and financing activity to programs in chronic hepatitis delta, PRO-XTEN® T-cell engagers, and preclinical infectious disease and oncology research.
SVF Endurance (Cayman) Limited reported multiple open‑market sales of Common Stock of VIR. The filing lists individual transactions between 11/24/2025 and 02/11/2026 with per‑trade share counts and proceeds, including large blocks such as 481,957 shares on 01/23/2026 for $3,652,848.49 and 291,270 shares on 01/22/2026 for $2,146,543.39.
Vanina A. Huard De Verneuil reported proposed sales of Common Stock under a Form 144 filed for Vir Biotechnology. The filing lists recent transfers of 4,445 shares on 02/23/2026 and 3,117 shares on 02/24/2026 with proceeds shown as $33,127.70 and $29,713.11, respectively.
The excerpt also shows restricted stock vesting events: 6,187 shares vested on 02/23/2026 and 7,513 shares vested on 02/24/2026.
Mark D. Eisner reported proposed sales of common stock of VIR under Rule 144. The notice lists a proposed sale through Fidelity Brokerage Services LLC of 1,889 common shares, dated 02/25/2026. The filing also records recent transactions: 2,089 shares sold on 02/23/2026 and 1,616 shares sold on 02/24/2026.
Vir Biotechnology SVP and Chief Accounting Officer Brent Sabatini reported both equity awards and an automatic tax-related sale of company stock. He received a grant of 25,000 shares of common stock as restricted stock units under Vir’s equity incentive plan and a stock option for 50,000 shares at an exercise price of $0.0000 per share. According to the vesting terms, 25% of the option will vest on February 22, 2027, with the remaining shares vesting in 36 equal monthly installments afterward. On February 23, 2026, 1,829 shares of common stock were sold at an average price of $7.4528 per share under a Rule 10b5-1 arrangement to satisfy tax withholding obligations tied to RSU vesting, and the filing states this sale was not a discretionary trade. After the tax-related sale, Sabatini directly owned 71,043 shares of Vir common stock, in addition to the newly granted 50,000 stock options.
Vir Biotechnology EVP & CFO Jason O'Byrne reported a mix of automatic tax-related sales and new equity awards. A total of 2,089 shares of common stock were sold on an open-market basis at $7.4528 per share under a Rule 10b5-1 arrangement solely to cover tax withholding on vesting restricted stock units, and the sale was not a discretionary trade.
On the prior day, O'Byrne received 55,000 shares of common stock as a restricted stock unit grant under the company’s equity incentive plan, bringing his common stock holdings to 166,338 shares at that time. He also received a stock option for 110,000 shares, with 25% vesting on February 22, 2027 and the remainder vesting in 36 equal monthly installments thereafter.
Vir Biotechnology EVP and Chief Medical Officer Mark Eisner reported a mix of stock grants and a small share sale. On February 22, 2026, he received 55,000 shares of common stock as a grant of restricted stock units and a stock option for 110,000 shares at an exercise price of $0.00. According to the terms, 25% of the option will vest on February 22, 2027, with the rest vesting in 36 equal monthly installments after that date. On February 23, 2026, 2,089 common shares were sold at an average price of $7.4528 per share under a Rule 10b5-1 arrangement to cover tax withholding on vesting RSUs, and this sale was described as automatic and mandatory rather than a discretionary trade. After these transactions, Eisner directly held 157,529 shares of common stock and the 110,000-share stock option.
Vir Biotechnology EVP and General Counsel Vanina de Verneuil reported a mix of stock sales and awards. On February 23, 2026, she completed an open-market sale of 4,445 shares of common stock at $7.4528 per share, described as an automatic, mandatory sale under a Rule 10b5-1 plan to cover tax withholding from vesting restricted stock units, rather than a discretionary trade. After this sale, she held 129,799 common shares directly.
On February 22, 2026, she acquired 55,000 shares of common stock through a grant of restricted stock units under the company’s equity incentive plan, and received a stock option for 110,000 shares. For the option, 25% of the shares will vest and become exercisable on February 22, 2027, with the remainder vesting in 36 equal monthly installments thereafter.
Vir Biotechnology, Inc. director and CEO Marianne De Backer reported both equity awards and a small share sale. On February 22, 2026, she received 570,000 stock options and 285,000 restricted stock units under the company’s equity plan, with options vesting 25% on February 22, 2027 and the rest in 36 monthly installments.
On February 23, 2026, 19,039 common shares were sold at $7.4528 per share in an automatic sale under a Rule 10b5-1 arrangement to cover tax withholding from RSU vesting, described as not a discretionary trade. After these transactions, she directly owned 1,035,466 common shares and indirectly held 53,118 shares via the Ureel-De Backer Family Trust.
VIR filed a Form 144 notice reporting proposed sales of common stock by an insider. The filing lists 1,616 common shares associated with restricted stock vesting on 02/23/2026 and records 2,089 common shares listed under securities sold during the past three months on 02/23/2026 by Mark D. Eisner.
The transactions are tied to compensation-related vesting and a broker-dealer record for Fidelity Brokerage Services LLC appears on 02/24/2026.
VIR notice of proposed sale: the filing shows 14,762 common shares listed as "Securities To Be Sold" on 02/23/2026 tied to restricted stock vesting and labeled "Issuer" for compensation.
The excerpt also records 19,039 common shares sold on 02/23/2026 by Marianne De Backer. Transaction counterparties and cash‑flow treatment are not stated in the provided excerpt.